Sikander Ailawadhi, MD

Articles

Dr Ailawadhi on Early Data for Iopofosine I 131 in Waldenström Macroglobulinemia

March 8th 2024

Sikander Ailawadhi, MD, discusses early efficacy and safety data for iopofosine I 131 monotherapy in Waldenström macroglobulinemia.

Dr Ailawadhi on Non-BCMA CAR T-Cell Therapies Under Investigation in Multiple Myeloma

January 15th 2024

Sikander Ailawadhi, MD, discusses non-BCMA CAR T-cell therapies currently under investigation in multiple myeloma.

Dr Ailawadhi on the Potential Sequencing of Bispecific Antibodies in Multiple Myeloma

January 12th 2024

Sikander Ailawadhi, MD, shares considerations for the potential sequencing of bispecific antibodies and other BCMA-directed therapies in multiple myeloma.

Dr Ailawadhi on Iopofosine I-131 in Waldenström Macroglobulinemia

January 5th 2024

Sikander Ailawadhi, MD, oncologist, Department of Hematology, CAR T-Cell Therapy Program, Mayo Clinic, discusses how the investigational agent iopofosine I-131 may address unmet needs for patients with Waldenström macroglobulinemia.

Final Thoughts on Case Study and Treating Multiple Myeloma

January 12th 2023

Dr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.

Clinical Trials in R/R Multiple Myeloma

January 12th 2023

Dr Joseph Mikhael and expert panel discuss key efficacy and safety outcomes of pivotal clinical trials evaluating treatment regimens in patients with R/R multiple myeloma.

Treatment Options in Early Relapse Multiple Myeloma

January 5th 2023

Dr Joseph Mikhael and expert panel review current treatment options for patients with early relapse multiple myeloma, in accordance with current NCCN guidelines.

Case Study: Myeloma at Early Relapse

January 5th 2023

Dr Joseph Mikhael and expert panel review a case study in early relapse multiple myeloma and the impact of cytogenetics in risk assessment for patients with early relapse multiple myeloma.

Frontline Therapy in Multiple Myeloma

December 22nd 2022

Joseph Mikhael, MD, discusses diagnosis criteria and treatment considerations for patients with multiple myeloma in the frontline setting.

Disparities in Multiple Myeloma Care: The Path Toward Health Equity

October 28th 2022

Expert panelists share their closing thoughts on the path to improve health equity in multiple myeloma management for racial and ethnic minority groups.

Addressing Healthcare Provider Bias in Multiple Myeloma Management

October 21st 2022

Joint consideration for physician bias in the management of multiple myeloma and how it can be addressed while treating patients belonging to racial and ethnic minority groups.

Improving Access to Clinical Trials in Multiple Myeloma

October 21st 2022

Centering discussion clinical trials in multiple myeloma, panelists review how to improve access to these studies for racial and ethnic minority groups.

Improving Access to Specialty Care in Multiple Myeloma

October 14th 2022

Experts on multiple myeloma share comprehensive insight on how to build better access to specialty care for patients of racial and ethnic minority groups.

Overcoming Barriers to Early Diagnosis in Multiple Myeloma

October 14th 2022

Expert perspectives on how to improve the early detection of multiple myeloma within patients belonging to racial and ethnic minority groups.

Multiple Myeloma: Disparities in Access to Transplantation and Novel Therapy

October 7th 2022

Closing out their review of the barriers racial and ethnic minority groups encounter in receiving care, expert panelists address access to transplantation or novel therapy.

Multiple Myeloma: Disparities in Access to Specialized Care

October 7th 2022

Comprehensive discussion on access to specialized care and how racial and ethnic minority groups encounter barriers in this setting.

Multiple Myeloma: Disparities in Time to Diagnosis

September 30th 2022

Panelists address how racial and ethnic minority groups experience disparity in time to diagnosis within the multiple myeloma treatment pathway.

Societal Determinants of Health in Multiple Myeloma

September 30th 2022

Expert panelists shift their attention to how social determinants of multiple myeloma impact the treatment received by racial and ethnic minority groups.

Biological Determinants of Health in Multiple Myeloma

September 23rd 2022

Focused discussion on the biological determinants of multiple myeloma and how its prevalence is reflected in racial and ethnic minority groups.

Overview of Multiple Myeloma and Health Equity

September 23rd 2022

Joseph Mikhael, MD, spearheads an overview on the prevalence of multiple myeloma in racial and ethnic minority groups in the context of health equity.